Stock comparison
AstraZeneca PLC is 2.4x more valuable than Bristol-Myers Squibb Company by market capitalization ($286.27 B vs $118.31 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
AZN is larger
AstraZeneca PLC is 2.4x more valuable than Bristol-Myers Squibb Company by market capitalization ($286.27 B vs $118.31 B).
Market value leader
AZN
AstraZeneca PLC is 2.4x more valuable than Bristol-Myers Squibb Company by market capitalization ($286.27 B vs $118.31 B).
| Metric | BMY | AZN |
|---|---|---|
| Market cap | $118.31 B | $286.27 B |
| US-listed rank | #136 | #50 |
| Revenue (latest FY) | $48.19B | - |
| Net income (latest FY) | $7.05B | - |
| Net margin | 14.6% | - |
| P/E (trailing FY) | 16.8x | - |
| SEC filings | 1,000 | 1,004 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
AstraZeneca PLC is 2.4x more valuable than Bristol-Myers Squibb Company by market capitalization ($286.27 B vs $118.31 B).
Full pages: Bristol-Myers Squibb Company and AstraZeneca PLC, or browse the full rankings.